{"transactions":[{"id":697723,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":26783,"kind":"person","name":"Weston Claire","position":1,"cik":"0002060874","reported_name":"Weston Claire","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-05T00:45:56.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through August 3, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":6.11,"expiration_date":"2036-08-03","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001140361-26-031326","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126031326/form4.xml","form_type":"4"}},{"id":697721,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":26782,"kind":"person","name":"Kirkby Maxwell","position":1,"cik":"0002060862","reported_name":"Kirkby Maxwell","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-05T00:39:56.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through August 3, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":6.11,"expiration_date":"2036-08-03","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001140361-26-031324","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126031324/form4.xml","form_type":"4"}},{"id":723082,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34559,"kind":"person","name":"Carmichael Gordon","position":1,"cik":"0001982077","reported_name":"Carmichael Gordon","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T22:17:37.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001140361-26-027008","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126027008/form4.xml","form_type":"4"}},{"id":723081,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34558,"kind":"person","name":"Epstein David M.","position":1,"cik":"0001488668","reported_name":"Epstein David M.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T22:17:35.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001140361-26-027007","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126027007/form4.xml","form_type":"4"}},{"id":723080,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34557,"kind":"person","name":"Weng Dan","position":1,"cik":"0002083482","reported_name":"Weng Dan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T22:17:34.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001140361-26-027006","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126027006/form4.xml","form_type":"4"}},{"id":723079,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34556,"kind":"person","name":"Parry Renate","position":1,"cik":"0001982817","reported_name":"Parry Renate","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T22:17:32.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001140361-26-027005","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126027005/form4.xml","form_type":"4"}},{"id":723078,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34555,"kind":"person","name":"Zhang Ping","position":1,"cik":"0002050176","reported_name":"Zhang Ping","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T22:17:31.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001140361-26-027004","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126027004/form4.xml","form_type":"4"}},{"id":723077,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34554,"kind":"person","name":"Nussbaum Rodney L","position":1,"cik":"0002014225","reported_name":"Nussbaum Rodney L","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-30T22:17:29.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":". This option represents a right to purchase a total of 40,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 10, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":40000,"derivative":{"exercise_price":5.95,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001140361-26-027003","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126027003/form4.xml","form_type":"4"}},{"id":730889,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:02:41.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are vested in full."}],"balance_after":827701,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001140361-26-025950","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025950/form4.xml","form_type":"4"}},{"id":730888,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:02:41.000Z","date":"2026-06-10","kind":"exercise","planned":false,"acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are vested in full."}],"balance_after":830701,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001140361-26-025950","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025950/form4.xml","form_type":"4"}},{"id":730887,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:02:41.000Z","date":"2026-06-09","kind":"exercise","planned":false,"acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are vested in full."}],"balance_after":835701,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001140361-26-025950","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025950/form4.xml","form_type":"4"}},{"id":730886,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-22T20:02:41.000Z","date":"2026-06-18","kind":"sale","planned":false,"acquired":false,"shares":3000,"price":6.35,"value":19050.0,"ownership":{"direct":true},"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-025950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025950/form4.xml","form_type":"4"}},{"id":730885,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-22T20:02:41.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":0.75,"value":2250.0,"ownership":{"direct":true},"balance_after":703000,"source":{"system":"sec-edgar","filing":"0001140361-26-025950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025950/form4.xml","form_type":"4"}},{"id":730884,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-22T20:02:41.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":5000,"price":6.24,"value":31200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.20 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-025950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025950/form4.xml","form_type":"4"}},{"id":730883,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-22T20:02:41.000Z","date":"2026-06-10","kind":"exercise","planned":false,"acquired":true,"shares":5000,"price":0.75,"value":3750.0,"ownership":{"direct":true},"balance_after":705000,"source":{"system":"sec-edgar","filing":"0001140361-26-025950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025950/form4.xml","form_type":"4"}},{"id":730882,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-22T20:02:41.000Z","date":"2026-06-09","kind":"sale","planned":false,"acquired":false,"shares":3000,"price":6.15,"value":18450.0,"ownership":{"direct":true},"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-025950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025950/form4.xml","form_type":"4"}},{"id":730881,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-22T20:02:41.000Z","date":"2026-06-09","kind":"exercise","planned":false,"acquired":true,"shares":3000,"price":0.75,"value":2250.0,"ownership":{"direct":true},"balance_after":703000,"source":{"system":"sec-edgar","filing":"0001140361-26-025950","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025950/form4.xml","form_type":"4"}},{"id":738263,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-15T20:01:12.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":false,"shares":2800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are vested in full."}],"balance_after":838701,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":2800},"source":{"system":"sec-edgar","filing":"0001140361-26-025208","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025208/form4.xml","form_type":"4"}},{"id":738262,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-15T20:01:12.000Z","date":"2026-06-11","kind":"sale","planned":false,"acquired":false,"shares":2800,"price":6.17,"value":17276.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.16 to $6.18. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-025208","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025208/form4.xml","form_type":"4"}},{"id":738261,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-15T20:01:12.000Z","date":"2026-06-11","kind":"exercise","planned":false,"acquired":true,"shares":2800,"price":0.75,"value":2100.0,"ownership":{"direct":true},"balance_after":702800,"source":{"system":"sec-edgar","filing":"0001140361-26-025208","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126025208/form4.xml","form_type":"4"}},{"id":742098,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:01:15.000Z","date":"2026-06-10","kind":"exercise","planned":false,"acquired":false,"shares":6418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":841501,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":6418},"source":{"system":"sec-edgar","filing":"0001140361-26-024929","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024929/form4.xml","form_type":"4"}},{"id":742097,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-11T20:01:15.000Z","date":"2026-06-09","kind":"exercise","planned":false,"acquired":false,"shares":14500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":847919,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":14500},"source":{"system":"sec-edgar","filing":"0001140361-26-024929","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024929/form4.xml","form_type":"4"}},{"id":742096,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-11T20:01:15.000Z","date":"2026-06-10","kind":"sale","planned":false,"acquired":false,"shares":6418,"price":6.21,"value":39855.78,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.11 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-024929","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024929/form4.xml","form_type":"4"}},{"id":742095,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-11T20:01:15.000Z","date":"2026-06-10","kind":"exercise","planned":false,"acquired":true,"shares":6418,"price":0.75,"value":4813.5,"ownership":{"direct":true},"balance_after":706418,"source":{"system":"sec-edgar","filing":"0001140361-26-024929","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024929/form4.xml","form_type":"4"}},{"id":742094,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-11T20:01:15.000Z","date":"2026-06-09","kind":"sale","planned":false,"acquired":false,"shares":14500,"price":6.14,"value":89030.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0597 to $6.19. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-024929","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024929/form4.xml","form_type":"4"}},{"id":742093,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-11T20:01:15.000Z","date":"2026-06-09","kind":"exercise","planned":false,"acquired":true,"shares":14500,"price":0.75,"value":10875.0,"ownership":{"direct":true},"balance_after":714500,"source":{"system":"sec-edgar","filing":"0001140361-26-024929","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024929/form4.xml","form_type":"4"}},{"id":743530,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39753,"kind":"person","name":"Bergmann Joshua Benjamin","position":1,"cik":"0002131863","reported_name":"Bergmann Joshua Benjamin","relationship":{"officer":true,"officer_title":"GC and Corporate Secretary"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:13:36.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":6.05,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-26-024785","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024785/form4.xml","form_type":"4"}},{"id":743529,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T20:13:08.000Z","date":"2026-06-08","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 120,000 shares of the Issuer's common stock, 25% of which will vest on June 8, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":120000,"derivative":{"exercise_price":6.05,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001140361-26-024784","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024784/form4.xml","form_type":"4"}},{"id":746668,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:01:20.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":false,"shares":15401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":862419,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":15401},"source":{"system":"sec-edgar","filing":"0001140361-26-024449","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024449/form4.xml","form_type":"4"}},{"id":746667,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-08T20:01:20.000Z","date":"2026-06-04","kind":"exercise","planned":false,"acquired":false,"shares":19575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":877820,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":19575},"source":{"system":"sec-edgar","filing":"0001140361-26-024449","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024449/form4.xml","form_type":"4"}},{"id":746666,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-08T20:01:20.000Z","date":"2026-06-05","kind":"sale","planned":false,"acquired":false,"shares":15401,"price":6.4,"value":98566.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.15 to $6.60. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-024449","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024449/form4.xml","form_type":"4"}},{"id":746665,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-08T20:01:20.000Z","date":"2026-06-05","kind":"exercise","planned":false,"acquired":true,"shares":15401,"price":0.75,"value":11550.75,"ownership":{"direct":true},"balance_after":715401,"source":{"system":"sec-edgar","filing":"0001140361-26-024449","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024449/form4.xml","form_type":"4"}},{"id":746664,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-08T20:01:20.000Z","date":"2026-06-04","kind":"sale","planned":false,"acquired":false,"shares":19575,"price":6.13,"value":119994.75,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-024449","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024449/form4.xml","form_type":"4"}},{"id":746663,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-06-08T20:01:20.000Z","date":"2026-06-04","kind":"exercise","planned":false,"acquired":true,"shares":19575,"price":0.75,"value":14681.25,"ownership":{"direct":true},"balance_after":719575,"source":{"system":"sec-edgar","filing":"0001140361-26-024449","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126024449/form4.xml","form_type":"4"}},{"id":762429,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-27T20:01:25.000Z","date":"2026-05-26","kind":"exercise","planned":false,"acquired":false,"shares":4000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are vested in full."}],"balance_after":897395,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":4000},"source":{"system":"sec-edgar","filing":"0001140361-26-022980","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022980/form4.xml","form_type":"4"}},{"id":762428,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-27T20:01:25.000Z","date":"2026-05-22","kind":"exercise","planned":false,"acquired":false,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options are vested in full."}],"balance_after":901395,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001140361-26-022980","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022980/form4.xml","form_type":"4"}},{"id":762427,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-27T20:01:25.000Z","date":"2026-05-26","kind":"sale","planned":false,"acquired":false,"shares":4000,"price":6.1001,"value":24400.4,"ownership":{"direct":true},"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-022980","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022980/form4.xml","form_type":"4"}},{"id":762426,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-27T20:01:25.000Z","date":"2026-05-26","kind":"exercise","planned":false,"acquired":true,"shares":4000,"price":0.75,"value":3000.0,"ownership":{"direct":true},"balance_after":704000,"source":{"system":"sec-edgar","filing":"0001140361-26-022980","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022980/form4.xml","form_type":"4"}},{"id":762425,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-27T20:01:25.000Z","date":"2026-05-22","kind":"sale","planned":false,"acquired":false,"shares":3500,"price":6.08,"value":21280.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.04 to $6.1051. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-022980","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022980/form4.xml","form_type":"4"}},{"id":762424,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-27T20:01:25.000Z","date":"2026-05-22","kind":"exercise","planned":false,"acquired":true,"shares":3500,"price":0.75,"value":2625.0,"ownership":{"direct":true},"balance_after":703500,"source":{"system":"sec-edgar","filing":"0001140361-26-022980","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022980/form4.xml","form_type":"4"}},{"id":766511,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T22:19:30.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":false,"shares":12820,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":904895,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":12820},"source":{"system":"sec-edgar","filing":"0001140361-26-022642","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022642/form4.xml","form_type":"4"}},{"id":766510,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-22T22:19:30.000Z","date":"2026-05-20","kind":"exercise","planned":false,"acquired":false,"shares":9400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":917715,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":9400},"source":{"system":"sec-edgar","filing":"0001140361-26-022642","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022642/form4.xml","form_type":"4"}},{"id":766509,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-22T22:19:30.000Z","date":"2026-05-21","kind":"sale","planned":false,"acquired":false,"shares":12820,"price":6.15,"value":78843.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.05 to $6.22. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-022642","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022642/form4.xml","form_type":"4"}},{"id":766508,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-22T22:19:30.000Z","date":"2026-05-21","kind":"exercise","planned":false,"acquired":true,"shares":12820,"price":0.75,"value":9615.0,"ownership":{"direct":true},"balance_after":712820,"source":{"system":"sec-edgar","filing":"0001140361-26-022642","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022642/form4.xml","form_type":"4"}},{"id":766507,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-22T22:19:30.000Z","date":"2026-05-20","kind":"sale","planned":false,"acquired":false,"shares":9400,"price":6.15,"value":57810.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.0908 to $6.2935. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-022642","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022642/form4.xml","form_type":"4"}},{"id":766506,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-22T22:19:30.000Z","date":"2026-05-20","kind":"exercise","planned":false,"acquired":true,"shares":9400,"price":0.75,"value":7050.0,"ownership":{"direct":true},"balance_after":709400,"source":{"system":"sec-edgar","filing":"0001140361-26-022642","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022642/form4.xml","form_type":"4"}},{"id":770397,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34555,"kind":"person","name":"Zhang Ping","position":1,"cik":"0002050176","reported_name":"Zhang Ping","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-21T01:03:16.000Z","date":"2026-05-14","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The option was canceled by mutual agreement of the Reporting Person and the Issuer. The Issuer shall provide the Reporting Person with consideration for the cancellation of the option, the form and amount of which shall be determined by the Issuer in its sole discretion; provided that such consideration shall not be economic in value."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The option was canceled by mutual agreement of the Reporting Person and the Issuer. The Issuer shall provide the Reporting Person with consideration for the cancellation of the option, the form and amount of which shall be determined by the Issuer in its sole discretion; provided that such consideration shall not be economic in value."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled option represented a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which would have vested on May 27, 2026, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":0,"derivative":{"exercise_price":10.18,"expiration_date":"2035-05-27","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001140361-26-022303","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022303/form4.xml","form_type":"4"}},{"id":770403,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:01:24.000Z","date":"2026-05-19","kind":"exercise","planned":false,"acquired":false,"shares":9120,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":927115,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":9120},"source":{"system":"sec-edgar","filing":"0001140361-26-022235","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022235/form4.xml","form_type":"4"}},{"id":770402,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-20T20:01:24.000Z","date":"2026-05-18","kind":"exercise","planned":false,"acquired":false,"shares":200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":936235,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":200},"source":{"system":"sec-edgar","filing":"0001140361-26-022235","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022235/form4.xml","form_type":"4"}},{"id":770401,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:01:24.000Z","date":"2026-05-19","kind":"sale","planned":false,"acquired":false,"shares":9120,"price":6.37,"value":58094.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.3002 to $6.4119. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-022235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022235/form4.xml","form_type":"4"}},{"id":770400,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:01:24.000Z","date":"2026-05-19","kind":"exercise","planned":false,"acquired":true,"shares":9120,"price":0.75,"value":6840.0,"ownership":{"direct":true},"balance_after":709120,"source":{"system":"sec-edgar","filing":"0001140361-26-022235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022235/form4.xml","form_type":"4"}},{"id":770399,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:01:24.000Z","date":"2026-05-18","kind":"sale","planned":false,"acquired":false,"shares":200,"price":6.62,"value":1324.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.6102 to $6.6215. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-022235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022235/form4.xml","form_type":"4"}},{"id":770398,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-20T20:01:24.000Z","date":"2026-05-18","kind":"exercise","planned":false,"acquired":true,"shares":200,"price":0.75,"value":150.0,"ownership":{"direct":true},"balance_after":700200,"source":{"system":"sec-edgar","filing":"0001140361-26-022235","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126022235/form4.xml","form_type":"4"}},{"id":775557,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T20:01:22.000Z","date":"2026-05-15","kind":"exercise","planned":false,"acquired":false,"shares":13100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":936435,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":13100},"source":{"system":"sec-edgar","filing":"0001140361-26-021889","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126021889/form4.xml","form_type":"4"}},{"id":775556,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T20:01:22.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":false,"shares":15580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are vested in full."}],"balance_after":949535,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":15580},"source":{"system":"sec-edgar","filing":"0001140361-26-021889","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126021889/form4.xml","form_type":"4"}},{"id":775555,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-18T20:01:22.000Z","date":"2026-05-15","kind":"sale","planned":false,"acquired":false,"shares":13100,"price":6.65,"value":87115.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.58 to $6.85. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-021889","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126021889/form4.xml","form_type":"4"}},{"id":775554,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-18T20:01:22.000Z","date":"2026-05-15","kind":"exercise","planned":false,"acquired":true,"shares":13100,"price":0.75,"value":9825.0,"ownership":{"direct":true},"balance_after":713100,"source":{"system":"sec-edgar","filing":"0001140361-26-021889","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126021889/form4.xml","form_type":"4"}},{"id":775553,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-18T20:01:22.000Z","date":"2026-05-14","kind":"sale","planned":false,"acquired":false,"shares":15580,"price":6.91,"value":107657.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.8326 to $7.28. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-26-021889","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126021889/form4.xml","form_type":"4"}},{"id":775552,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2026-05-18T20:01:22.000Z","date":"2026-05-14","kind":"exercise","planned":false,"acquired":true,"shares":15580,"price":0.75,"value":11685.0,"ownership":{"direct":true},"balance_after":715580,"source":{"system":"sec-edgar","filing":"0001140361-26-021889","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126021889/form4.xml","form_type":"4"}},{"id":788761,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-08T01:58:29.000Z","date":"2026-05-06","kind":"sale","planned":true,"acquired":false,"shares":10136,"price":8.04,"value":81493.44,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $8.00 to $8.071. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2565226,"source":{"system":"sec-edgar","filing":"0001140361-26-019658","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019658/form4.xml","form_type":"4"}},{"id":788760,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":39752,"kind":"person","name":"Luo Ying","position":1,"cik":"0001959160","reported_name":"Luo Ying","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-05-08T01:58:29.000Z","date":"2026-05-05","kind":"sale","planned":true,"acquired":false,"shares":179,"price":8.01,"value":1433.79,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2025."}],"balance_after":2575362,"source":{"system":"sec-edgar","filing":"0001140361-26-019658","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019658/form4.xml","form_type":"4"}},{"id":790259,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49435,"kind":"organization","name":"GNI Group Ltd.","position":1,"cik":"0001958461","reported_name":"GNI Group Ltd.","relationship":{"ten_percent_owner":true}},{"id":49436,"kind":"organization","name":"GNI USA, Inc.","position":2,"cik":"0001973229","reported_name":"GNI USA, Inc.","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2026-05-07T00:40:53.000Z","date":"2026-05-04","kind":"other","planned":false,"acquired":true,"shares":2143706,"ownership":{"direct":false,"nature":"See Remarks"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"shares","element":"transactionShares","label":"F2","text":"Effective as of May 4, 2026 (the \"Effective Time\"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. (\"Cullgen\") with Cullgen surviving as a wholly-owned subsidiary of the Issuer (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Person prior to the Merger. Each share of capital stock of Cullgen held at the Effective Time was exchanged for 0.4753 divided by five shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective as of May 4, 2026 (the \"Effective Time\"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. (\"Cullgen\") with Cullgen surviving as a wholly-owned subsidiary of the Issuer (the \"Merger\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Person prior to the Merger. Each share of capital stock of Cullgen held at the Effective Time was exchanged for 0.4753 divided by five shares of Series B Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are held by GNI USA. GNI Japan may be deemed for purposes of Section 16 of the Exchange Act to be the indirect beneficial owner of the securities held by GNI USA."}],"balance_after":2143706,"derivative":{"underlying":"Common Stock","underlying_shares":10718530},"source":{"system":"sec-edgar","filing":"0001140361-26-019378","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019378/form4.xml","form_type":"4"}},{"id":790258,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49435,"kind":"organization","name":"GNI Group Ltd.","position":1,"cik":"0001958461","reported_name":"GNI Group Ltd.","relationship":{"ten_percent_owner":true}},{"id":49436,"kind":"organization","name":"GNI USA, Inc.","position":2,"cik":"0001973229","reported_name":"GNI USA, Inc.","relationship":{"ten_percent_owner":true}}],"security":"Series B Preferred Stock","published_at":"2026-05-07T00:40:53.000Z","date":"2026-05-04","kind":"other","planned":false,"acquired":true,"shares":458120,"ownership":{"direct":false,"nature":"See Remarks"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"shares","element":"transactionShares","label":"F2","text":"Effective as of May 4, 2026 (the \"Effective Time\"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. (\"Cullgen\") with Cullgen surviving as a wholly-owned subsidiary of the Issuer (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Person prior to the Merger. Each share of capital stock of Cullgen held at the Effective Time was exchanged for 0.4753 divided by five shares of Series B Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Following Stockholder Approval, each share of Series B Preferred Stock will be convertible, at the option of the holder, into five shares of common stock, subject to certain limitations, including the Beneficial Ownership Limitation (as such terms are defined in the Certificate of Designation for Series B Preferred Stock filed with the Securities and Exchange Commission as Exhibit 3.1 to the Issuer's Form 8-K filed on March 2, 2026)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The Series B Preferred Stock has no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Effective as of May 4, 2026 (the \"Effective Time\"), a wholly-owned subsidiary of the Issuer merged with and into Cullgen Inc. (\"Cullgen\") with Cullgen surviving as a wholly-owned subsidiary of the Issuer (the \"Merger\")."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Represents the number of shares of Series B Preferred Stock of the Issuer received by the Reporting Person in the Merger in exchange for the shares of capital stock of Cullgen held by the Reporting Person prior to the Merger. Each share of capital stock of Cullgen held at the Effective Time was exchanged for 0.4753 divided by five shares of Series B Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"These securities are held by GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (\"GNI Japan\"). GNI USA, Inc., a Delaware corporation (\"GNI USA\") is a wholly-owned subsidiary of GNI Japan. GNI USA may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), to be the indirect beneficial owner of the securities held by GNI Japan."}],"balance_after":458120,"derivative":{"underlying":"Common Stock","underlying_shares":2290600},"source":{"system":"sec-edgar","filing":"0001140361-26-019378","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019378/form4.xml","form_type":"4"}},{"id":790257,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49434,"kind":"person","name":"Eastling Thomas Wilson","position":1,"cik":"0001958487","reported_name":"Eastling Thomas Wilson","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T00:38:03.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":33271,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":33271,"derivative":{"exercise_price":0.32,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":33271},"source":{"system":"sec-edgar","filing":"0001140361-26-019376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019376/form4.xml","form_type":"4"}},{"id":790256,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49434,"kind":"person","name":"Eastling Thomas Wilson","position":1,"cik":"0001958487","reported_name":"Eastling Thomas Wilson","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T00:38:03.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":92683,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option represents a right to purchase 92,683 shares of the Issuer's common stock, one quarter of which vested on November 13, 2025, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date."}],"balance_after":92683,"derivative":{"exercise_price":5.98,"expiration_date":"2034-11-12","underlying":"Common Stock","underlying_shares":92683},"source":{"system":"sec-edgar","filing":"0001140361-26-019376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019376/form4.xml","form_type":"4"}},{"id":790255,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49434,"kind":"person","name":"Eastling Thomas Wilson","position":1,"cik":"0001958487","reported_name":"Eastling Thomas Wilson","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T00:38:03.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":95060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":95060,"derivative":{"exercise_price":2.34,"expiration_date":"2032-01-23","underlying":"Common Stock","underlying_shares":95060},"source":{"system":"sec-edgar","filing":"0001140361-26-019376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019376/form4.xml","form_type":"4"}},{"id":790254,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49434,"kind":"person","name":"Eastling Thomas Wilson","position":1,"cik":"0001958487","reported_name":"Eastling Thomas Wilson","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T00:38:03.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":33271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":33271,"derivative":{"exercise_price":2,"expiration_date":"2031-06-09","underlying":"Common Stock","underlying_shares":33271},"source":{"system":"sec-edgar","filing":"0001140361-26-019376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019376/form4.xml","form_type":"4"}},{"id":790253,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49434,"kind":"person","name":"Eastling Thomas Wilson","position":1,"cik":"0001958487","reported_name":"Eastling Thomas Wilson","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T00:38:03.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":11882,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":11882,"derivative":{"exercise_price":2,"expiration_date":"2030-12-17","underlying":"Common Stock","underlying_shares":11882},"source":{"system":"sec-edgar","filing":"0001140361-26-019376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019376/form4.xml","form_type":"4"}},{"id":790252,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49434,"kind":"person","name":"Eastling Thomas Wilson","position":1,"cik":"0001958487","reported_name":"Eastling Thomas Wilson","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T00:38:03.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":47530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":47530,"derivative":{"exercise_price":0.93,"expiration_date":"2030-01-12","underlying":"Common Stock","underlying_shares":47530},"source":{"system":"sec-edgar","filing":"0001140361-26-019376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019376/form4.xml","form_type":"4"}},{"id":790251,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49434,"kind":"person","name":"Eastling Thomas Wilson","position":1,"cik":"0001958487","reported_name":"Eastling Thomas Wilson","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-07T00:38:03.000Z","date":"2026-05-04","kind":"grant","planned":false,"acquired":true,"shares":95060,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option is fully vested."}],"balance_after":95060,"derivative":{"exercise_price":0.32,"expiration_date":"2028-06-07","underlying":"Common Stock","underlying_shares":95060},"source":{"system":"sec-edgar","filing":"0001140361-26-019376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126019376/form4.xml","form_type":"4"}},{"id":942536,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34555,"kind":"person","name":"Zhang Ping","position":1,"cik":"0002050176","reported_name":"Zhang Ping","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:01:22.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 100,000 shares of the Issuer's common stock, 25% of which will vest on January 7, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":7.31,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001140361-26-000832","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126000832/form4.xml","form_type":"4"}},{"id":942535,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":69710,"kind":"person","name":"Chen Ruoyu","position":1,"cik":"0001982080","reported_name":"Chen Ruoyu","relationship":{"officer":true,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-09T21:01:14.000Z","date":"2026-01-07","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 50,000 shares of the Issuer's common stock, 25% of which will vest on January 7, 2027, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":50000,"derivative":{"exercise_price":7.31,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-26-000831","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036126000831/form4.xml","form_type":"4"}},{"id":1056007,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34557,"kind":"person","name":"Weng Dan","position":1,"cik":"0002083482","reported_name":"Weng Dan","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-26T20:09:36.000Z","date":"2025-08-18","kind":"grant","planned":false,"acquired":true,"shares":52000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 52,000 shares of the Issuer's common stock, which will vest in 36 equal monthly installments through August 18, 2028, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":52000,"derivative":{"exercise_price":7.85,"expiration_date":"2035-08-18","underlying":"Common Stock","underlying_shares":52000},"source":{"system":"sec-edgar","filing":"0001140361-25-032719","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125032719/form4.xml","form_type":"4"}},{"id":1072532,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34555,"kind":"person","name":"Zhang Ping","position":1,"cik":"0002050176","reported_name":"Zhang Ping","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T00:00:41.000Z","date":"2025-08-05","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which will vest on August 5, 2026, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":250000,"derivative":{"exercise_price":6.92,"expiration_date":"2035-08-05","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001140361-25-029693","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125029693/form4.xml","form_type":"4"}},{"id":1120086,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":49434,"kind":"person","name":"Eastling Thomas Wilson","position":1,"cik":"0001958487","reported_name":"Eastling Thomas Wilson","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:22:46.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 4, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001140361-25-021793","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125021793/form4.xml","form_type":"4"}},{"id":1120085,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34558,"kind":"person","name":"Epstein David M.","position":1,"cik":"0001488668","reported_name":"Epstein David M.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:22:42.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 4, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001140361-25-021792","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125021792/form4.xml","form_type":"4"}},{"id":1120084,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34554,"kind":"person","name":"Nussbaum Rodney L","position":1,"cik":"0002014225","reported_name":"Nussbaum Rodney L","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:22:36.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 4, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001140361-25-021791","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125021791/form4.xml","form_type":"4"}},{"id":1120083,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34556,"kind":"person","name":"Parry Renate","position":1,"cik":"0001982817","reported_name":"Parry Renate","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:22:25.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 4, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001140361-25-021790","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125021790/form4.xml","form_type":"4"}},{"id":1120082,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34559,"kind":"person","name":"Carmichael Gordon","position":1,"cik":"0001982077","reported_name":"Carmichael Gordon","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:22:20.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":26000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 26,000 shares of the Issuer's common stock, which will vest in 12 equal monthly installments through June 4, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":26000,"derivative":{"exercise_price":8.58,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":26000},"source":{"system":"sec-edgar","filing":"0001140361-25-021789","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125021789/form4.xml","form_type":"4"}},{"id":1130872,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-29T20:01:09.000Z","date":"2025-05-28","kind":"sale","planned":true,"acquired":false,"shares":558,"price":10.07,"value":5619.06,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.29. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2806084,"source":{"system":"sec-edgar","filing":"0001140361-25-020754","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020754/form4.xml","form_type":"4"}},{"id":1130871,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-29T20:01:09.000Z","date":"2025-05-27","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.28,"value":20560.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $11.44. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2806642,"source":{"system":"sec-edgar","filing":"0001140361-25-020754","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020754/form4.xml","form_type":"4"}},{"id":1132321,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":34555,"kind":"person","name":"Zhang Ping","position":1,"cik":"0002050176","reported_name":"Zhang Ping","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-28T22:13:58.000Z","date":"2025-05-27","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 250,000 shares of the Issuer's common stock, 25% of which will vest on May 27, 2026, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date."}],"balance_after":250000,"derivative":{"exercise_price":10.18,"expiration_date":"2035-05-27","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001140361-25-020669","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020669/form4.xml","form_type":"4"}},{"id":1133852,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-27T20:02:13.000Z","date":"2025-05-23","kind":"sale","planned":true,"acquired":false,"shares":182,"price":10.24,"value":1863.68,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2808642,"source":{"system":"sec-edgar","filing":"0001140361-25-020474","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020474/form4.xml","form_type":"4"}},{"id":1133851,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-27T20:02:13.000Z","date":"2025-05-22","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.97,"value":21940.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.215 to $11.27. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2808824,"source":{"system":"sec-edgar","filing":"0001140361-25-020474","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020474/form4.xml","form_type":"4"}},{"id":1137761,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-22T20:01:08.000Z","date":"2025-05-21","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.83,"value":21660.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.32 to $11.275. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2810824,"source":{"system":"sec-edgar","filing":"0001140361-25-020156","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020156/form4.xml","form_type":"4"}},{"id":1137760,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-22T20:01:08.000Z","date":"2025-05-20","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.25,"value":22500.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.925 to $11.42. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2812824,"source":{"system":"sec-edgar","filing":"0001140361-25-020156","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125020156/form4.xml","form_type":"4"}},{"id":1140870,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-20T20:01:17.000Z","date":"2025-05-19","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.11,"value":22220.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.02 to $11.215. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2814824,"source":{"system":"sec-edgar","filing":"0001140361-25-019893","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019893/form4.xml","form_type":"4"}},{"id":1140869,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-20T20:01:17.000Z","date":"2025-05-16","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.31,"value":22620.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.82 to $11.58. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2816824,"source":{"system":"sec-edgar","filing":"0001140361-25-019893","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019893/form4.xml","form_type":"4"}},{"id":1145901,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-16T20:01:12.000Z","date":"2025-05-15","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.68,"value":21360.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.435 to $10.93. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2818824,"source":{"system":"sec-edgar","filing":"0001140361-25-019468","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019468/form4.xml","form_type":"4"}},{"id":1145900,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-16T20:01:12.000Z","date":"2025-05-14","kind":"sale","planned":true,"acquired":false,"shares":20,"price":11.3,"value":226.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at price of $11.30. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2820824,"source":{"system":"sec-edgar","filing":"0001140361-25-019468","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019468/form4.xml","form_type":"4"}},{"id":1149604,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-15T00:21:22.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are vested in full."}],"balance_after":965115,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001140361-25-019053","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019053/form4.xml","form_type":"4"}},{"id":1149603,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-05-15T00:21:22.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":0.75,"value":37500.0,"ownership":{"direct":true},"balance_after":700000,"source":{"system":"sec-edgar","filing":"0001140361-25-019053","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125019053/form4.xml","form_type":"4"}},{"id":1149602,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-14T20:04:40.000Z","date":"2025-05-13","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":11.37,"value":22740.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.16 to $11.69. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2820844,"source":{"system":"sec-edgar","filing":"0001140361-25-018927","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125018927/form4.xml","form_type":"4"}},{"id":1149601,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":79123,"kind":"person","name":"Ma Songjiang","position":1,"cik":"0001985547","reported_name":"Ma Songjiang","relationship":{"director":true,"officer":true,"officer_title":"President"}}],"security":"Common Stock","published_at":"2025-05-14T20:04:40.000Z","date":"2025-05-12","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":10.56,"value":21120.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on September 13, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $10.00 to $10.885. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price."}],"balance_after":2822844,"source":{"system":"sec-edgar","filing":"0001140361-25-018927","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125018927/form4.xml","form_type":"4"}},{"id":1165862,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-25T20:01:13.000Z","date":"2025-03-27","kind":"exercise","planned":false,"acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are vested in full."}],"balance_after":1015115,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001140361-25-015712","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125015712/form4.xml","form_type":"4"}},{"id":1165861,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-25T20:01:13.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":false,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are vested in full."}],"balance_after":1165115,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001140361-25-015712","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125015712/form4.xml","form_type":"4"}},{"id":1165860,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-04-25T20:01:13.000Z","date":"2025-03-24","kind":"exercise","planned":false,"acquired":false,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options are vested in full."}],"balance_after":1365115,"derivative":{"exercise_price":0.75,"expiration_date":"2030-10-31","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001140361-25-015712","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125015712/form4.xml","form_type":"4"}},{"id":1165859,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-04-25T20:01:13.000Z","date":"2025-03-27","kind":"exercise","planned":false,"acquired":true,"shares":150000,"price":0.75,"value":112500.0,"ownership":{"direct":true},"balance_after":650000,"source":{"system":"sec-edgar","filing":"0001140361-25-015712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125015712/form4.xml","form_type":"4"}},{"id":1165858,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-04-25T20:01:13.000Z","date":"2025-03-26","kind":"exercise","planned":false,"acquired":true,"shares":200000,"price":0.75,"value":150000.0,"ownership":{"direct":true},"balance_after":500000,"source":{"system":"sec-edgar","filing":"0001140361-25-015712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125015712/form4.xml","form_type":"4"}},{"id":1165857,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":36464,"kind":"person","name":"Ye Weiguo","position":1,"cik":"0001985496","reported_name":"Ye Weiguo","relationship":{"officer":true,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2025-04-25T20:01:13.000Z","date":"2025-03-24","kind":"exercise","planned":false,"acquired":true,"shares":300000,"price":0.75,"value":225000.0,"ownership":{"direct":true},"balance_after":300000,"source":{"system":"sec-edgar","filing":"0001140361-25-015712","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036125015712/form4.xml","form_type":"4"}}],"next_cursor":"2025-04-25T20:01:13.000000Z,1165857"}